HK1212995A1 - A method of purifying proteins - Google Patents

A method of purifying proteins

Info

Publication number
HK1212995A1
HK1212995A1 HK16100830.6A HK16100830A HK1212995A1 HK 1212995 A1 HK1212995 A1 HK 1212995A1 HK 16100830 A HK16100830 A HK 16100830A HK 1212995 A1 HK1212995 A1 HK 1212995A1
Authority
HK
Hong Kong
Prior art keywords
purifying proteins
purifying
proteins
Prior art date
Application number
HK16100830.6A
Other languages
Chinese (zh)
Inventor
Nathan Brinkman
Original Assignee
Csl Behring Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/803,525 external-priority patent/US9534029B2/en
Application filed by Csl Behring Ag filed Critical Csl Behring Ag
Publication of HK1212995A1 publication Critical patent/HK1212995A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795Porphyrin- or corrin-ring-containing peptides
    • C07K14/805Haemoglobins; Myoglobins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/30Extraction; Separation; Purification by precipitation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1722Plasma globulins, lactoglobulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41Porphyrin- or corrin-ring-containing peptides
    • A61K38/42Haemoglobins; Myoglobins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/18Ion-exchange chromatography
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/36Extraction; Separation; Purification by a combination of two or more processes of different types
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4717Plasma globulins, lactoglobulin
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK16100830.6A 2012-10-03 2016-01-26 A method of purifying proteins HK1212995A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261709342P 2012-10-03 2012-10-03
US13/803,525 US9534029B2 (en) 2012-10-03 2013-03-14 Method of purifying proteins
AU2013203930A AU2013203930B2 (en) 2012-10-03 2013-04-11 A method of purifying proteins
EP13170202 2013-06-03
PCT/US2013/062916 WO2014055552A1 (en) 2012-10-03 2013-10-01 A method of purifying proteins

Publications (1)

Publication Number Publication Date
HK1212995A1 true HK1212995A1 (en) 2016-06-24

Family

ID=52824845

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16100830.6A HK1212995A1 (en) 2012-10-03 2016-01-26 A method of purifying proteins

Country Status (8)

Country Link
EP (1) EP2904005A1 (en)
JP (2) JP6370792B2 (en)
KR (2) KR102125695B1 (en)
CN (2) CN104968676A (en)
CA (2) CA3129057C (en)
HK (1) HK1212995A1 (en)
SG (1) SG11201501921SA (en)
WO (1) WO2014055552A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2887588T3 (en) * 2015-08-13 2021-12-23 Kamada Ltd Compositions derived from Cohn's fraction paste and use thereof
US20190276521A1 (en) * 2016-03-29 2019-09-12 Kyowa Hakko Kirin Co., Ltd. Therapeutic agent for treatment of autoimmune diseases containing antibody binding to haptoglobin in blood and forming polyvalent immune complex as an active component
AU2018314767B2 (en) * 2017-08-08 2024-03-21 Csl Behring Ag Hemopexin formulations
EP3783359B1 (en) * 2018-04-18 2024-03-27 Sekisui Medical Co., Ltd. Haemoglobin analysis method
EP3968988A1 (en) 2019-05-17 2022-03-23 Universität Zürich Haptoglobin for use in treating an adverse secondary neurological outcome following a haemorrhagic stroke
CN117136068A (en) 2021-02-01 2023-11-28 瑞士杰特贝林生物制品有限公司 Method for treating or preventing adverse secondary neurological consequences after hemorrhagic stroke
US20240034749A1 (en) * 2021-02-04 2024-02-01 Green Cross Corporation Method for purification of hemopexin and haptoglobin
WO2024134608A1 (en) 2022-12-22 2024-06-27 Csl Behring Ag Method of purifying hemopexin using mixed-mode chromatography

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5337406B2 (en) * 1973-11-15 1978-10-09
GB1426039A (en) * 1973-11-15 1976-02-25 Green Cross Corp Haptoglobin in aqueous solution and process for tits preparation
US4129648A (en) * 1977-11-21 1978-12-12 Collier Harry O J Method for reducing endogenous prostaglandin synthesis
US4764369A (en) 1983-07-14 1988-08-16 New York Blood Center Inc. Undenatured virus-free biologically active protein derivatives
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
JPS6317899A (en) * 1986-07-09 1988-01-25 Green Cross Corp:The Purification of haptoglobin
JPH01305036A (en) * 1988-05-31 1989-12-08 Green Cross Corp:The Heat-treatment of plasma protein component and drug preparation containing plasma protein component
US5169936A (en) * 1989-04-14 1992-12-08 Biogen, Inc. Protein purification on immobilized metal affinity resins effected by elution using a weak ligand
US5138034A (en) * 1989-07-12 1992-08-11 The Green Cross Corporation Method of fractionating plasma proteins
FR2672604B1 (en) * 1991-02-07 1995-05-05 Pasteur Merieux Serums Vacc PROCESS FOR ISOLATING HUMAN ALBUMIN FROM SURNANTANT IV, PARTICULARLY IV-4, OR FRACTION V OF COHN OR OF A SURNANTANT OR THE LIKE FRACTION.
SE9301582D0 (en) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab PURIFICATION OF PLASMA PROTEINS
DE19830914C1 (en) * 1998-07-10 1999-06-24 Centeon Pharma Gmbh Preparation of a protein solution, especially albumin solution for use as blood volume substitute in emergency situations, and solution containing blood coagulation factors
US6093804A (en) * 1998-09-24 2000-07-25 American National Red Cross Method for purification of alpha-1 proteinase inhibitor
US6815181B2 (en) * 2001-07-09 2004-11-09 Applera Corporation Nucleic acid molecules encoding human secreted hemopexin-related proteins
DE10211632A1 (en) 2002-03-15 2003-10-09 Aventis Behring Gmbh Process for the separation of viruses from a protein solution by nanofiltration
DE10215315A1 (en) * 2002-04-05 2003-11-20 Aventis Behring Gmbh Intellect Human transferrin for the treatment of anemia of chronic disease (ACD) and functional iron deficiency
AU2002307776A1 (en) * 2002-04-16 2003-10-27 Kamada Ltd. Ultrapure transferrin for pharmaceutical compositions
DE10261126A1 (en) 2002-08-13 2004-03-04 Aventis Behring Gmbh Storage-stable, liquid fibrinogen formulation
JP2004224793A (en) * 2003-01-17 2004-08-12 Research Corp Technologies Inc Method of treating endometriosis
JP2004256463A (en) * 2003-02-26 2004-09-16 Univ Waseda Agent for inhibiting cell adhesion of polymorphonuclear leukocyte and method for inhibiting cell adhesion
GB0423196D0 (en) * 2004-10-19 2004-11-24 Nat Blood Authority Method
US7291338B2 (en) * 2005-03-09 2007-11-06 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
WO2007132291A2 (en) * 2006-05-15 2007-11-22 Digilab, Inc. Biomarkers for pre-form of type 2 diabetes and methods for detecting the presence of absence of a pre-form of type 2 diabetes
WO2009025754A2 (en) * 2007-08-17 2009-02-26 Csl Behring Gmbh Methods for purification of alpha-1-antitrypsin and apolipoprotein a-i
EP2027875A1 (en) * 2007-08-23 2009-02-25 Octapharma AG A Process for Isolation and Purification of a Target Protein free of Prion Protein (PrPSC)
KR101426039B1 (en) * 2008-09-11 2014-08-01 삼성테크윈 주식회사 Apparatus and method for extracting feature point to recognize face/object
FR2942233B1 (en) * 2009-02-19 2015-03-13 Lfb Biotechnologies MEANS FOR PURIFYING BLOOD PLASMA PROTEIN, AND METHODS FOR ITS IMPLEMENTATION
EP2236617A1 (en) * 2009-03-31 2010-10-06 Leukocare Ag Methods of terminal sterilization of biofunctional compositions
WO2011002070A1 (en) * 2009-07-02 2011-01-06 協和発酵キリン株式会社 Pharmaceutical composition for treating iron overload disorders or diseases on which the reduction in iron concentration is effective, which comprises gdf7/bmp12 protein
ES2426098T3 (en) * 2009-07-16 2013-10-21 Institut National de la Santé et de la Recherche Médicale Pharmaceutical compositions and their use in cancer treatment
ES2360782B1 (en) * 2009-07-28 2012-03-12 Grifols, S.A. Means for culturing mammalian cells comprising supernatant of stages of Cohn fractionation and use thereof.
CN102471368A (en) * 2009-08-11 2012-05-23 拜康有限公司 Chromatographic processes and purified compounds thereof
ES2545893T3 (en) * 2010-04-20 2015-09-16 Octapharma Ag New stabilizing agent for pharmaceutical proteins
WO2012050874A2 (en) * 2010-09-28 2012-04-19 Soares Miguel P Targeting heme for the treatment of immune mediated inflammatory diseases

Also Published As

Publication number Publication date
KR102231613B1 (en) 2021-03-25
CA3129057A1 (en) 2014-04-10
CN112717125A (en) 2021-04-30
JP6876655B2 (en) 2021-05-26
WO2014055552A1 (en) 2014-04-10
SG11201501921SA (en) 2015-04-29
KR102125695B1 (en) 2020-06-24
CA2886726A1 (en) 2014-04-10
EP2904005A1 (en) 2015-08-12
CN104968676A (en) 2015-10-07
CA2886726C (en) 2021-11-23
JP2018172426A (en) 2018-11-08
JP6370792B2 (en) 2018-08-08
KR20200075027A (en) 2020-06-25
JP2015532301A (en) 2015-11-09
KR20150063547A (en) 2015-06-09
CA3129057C (en) 2023-03-07

Similar Documents

Publication Publication Date Title
HRP20181357T1 (en) Novel protein purification methods
HK1214833A1 (en) A method of purifying therapeutic proteins
EP2883882A4 (en) Protein purification method
GB201217772D0 (en) Sequencing method
IL232558B (en) Antibody purification method
PT2768857T (en) Methods of purifying antibodies
ZA201305971B (en) Method for the purification of biphephos
HRP20190030T1 (en) Method of purifying an antibody
HK1212995A1 (en) A method of purifying proteins
EP2727930A4 (en) Method for purifying protein
SG11201405296QA (en) Method for purifying acetonitrile
GB201222693D0 (en) Novel method
SG10201606218WA (en) Purified Proteins
EP2697245A4 (en) Methods of purifying hydrophobin
GB201209082D0 (en) Purification method
GB201220155D0 (en) Method of manufacture
SG11201501216XA (en) Method for purifying acetonitrile
LT3202769T (en) Purification method for phosphaplatin compounds
EP2743258A4 (en) Method for purifying levo-oxiracetam
SG2013017017A (en) A method of separation
EP2737065A4 (en) Protein production method
EP2762486A4 (en) Method for purifying protein
GB201105407D0 (en) Purification method
SG10201703786YA (en) Nox removal method
GB201215942D0 (en) Method of treatent